Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
Critical Reviews in Oncology/Hematology|June 24, 2015
Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancerMiguel Ángel Climent, Luis León-Mateos, Aránzazu González Del Alba, et al.
BMC Medicine|August 23, 2015
A robust blood gene expression-based prognostic model for castration-resistant prostate cancerLi Wang, Yixuan Gong, Uma Chippada-Venkata, et al.
European Urology|January 26, 2021
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for CliniciansAxel S Merseburger, Nick Waldron, Maria J Ribal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trialsDavid Olmos, Richard D Baird, Timothy A Yap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2020
Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate CancerCarlos Perez-Ruixo, Oliver Ackaert, Daniele Ouellet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2013
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumorsAndré T Brunetto, Joo Ern Ang, Rohit Lal, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyXavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Sarcoma|December 27, 2013
Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcomaJuan Martin-Liberal, Salma Alam, Anastasia Constantinidou, et al.
Clinical Genitourinary Cancer|January 25, 2023
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Johann de Bono, Christopher Sweeney, et al.
British Journal of Cancer|March 23, 2016
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignanciesJoaquin Mateo, David Olmos, Herlinde Dumez, et al.
Pageof 13